Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2010. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a regulatory disclosure of share ownership changes and does not contain financial performance data.
Material Changes
On January 12, 2010, eight individuals acquired Ordinary shares through the Company's Share Reward Plan at a price of £12.99 per share. The individuals involved are Mr. A P Witty, Mr. J S Heslop, Mr. S M Bicknell, Mr. E J Gray, Mr. S A Hussain, Mr. D Learmouth, Mr. D S Redfern, and Ms. C Thomas.
- Each individual acquired 9 Ordinary shares under the partnership element (personal contribution).
- Each individual acquired 9 Ordinary shares under the matching element (Company contribution).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the share transactions described above in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of £12.99 per Ordinary share on January 12, 2010.
- Confirm the total number of shares acquired by each listed director (18 shares per person: 9 personal, 9 matched).
- Review the terms of the Company's Share Reward Plan to understand the matching contribution structure.